ONWARD reveals positive topline results of LIFT Home study

1055

ONWARD Medical has reported topline results from the LIFT Home study, which reported no serious adverse events and a 97% rate of successful session completion, thus supporting the home use of its ARC-EX therapy.

ARC-EX therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with spinal cord injury (SCI) and other movement disabilities.

The LIFT Home study is a single-arm observational study. The main objective of the study is to evaluate the safety and feasibility of ARC-EX therapy when used at home. A total of 17 people were enrolled at five leading SCI research centres in the USA.

Participants performed training on activities of daily living three times a week over a one-month period. According to ONWARD, approximately 97% of these sessions were completed without usability issues, supporting the feasibility of home-based treatment. The absence of any device-related adverse events confirmed the favourable safety results observed during the Up-LIFT study when ARC-EX therapy was used in clinics.

Dave Marver, CEO of ONWARD, said: “Today’s results from the LIFT Home study support the potential for ARC-EX therapy to be used safely at home, which would enable people with SCI to live even more independently. We expect to launch first in clinics, but as the community gains more experience with ARC-EX therapy, we envision many patients will also want to use this technology at home.”

Candy Tefertiller, principal investigator of the study and executive director of research and evaluation at Craig Hospital (Denver, USA), added: “To maximise recovery after SCI, it’s critical that we develop treatments that can be safely and effectively delivered in the home environment. Integrating home-based therapy not only facilitates opportunities for ongoing recovery, but also allows therapy to focus on more relevant activities for that specific individual.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here